⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AGEN News
Agenus Inc.
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
businesswire.com
AGEN
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
globenewswire.com
ONCY
AGEN
CRDF
EXEL
GILD
Empowering Better Outcomes: Mediaplanet Launches "Breast Health" Campaign
prnewswire.com
GEHC
AZN
SYK
AGEN
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
businesswire.com
AGEN
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
businesswire.com
AGEN
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
businesswire.com
AGEN
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
businesswire.com
AGEN
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
businesswire.com
AGEN
Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
businesswire.com
AGEN
France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
businesswire.com
AGEN